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Abstract
This study aimed to investigate the metabolic syndrome-related risk factors for the development of benign prostatic hyperplasia
(BPH) with lower urinary tract symptoms (LUTS) in healthy men.
A total of 4880 healthy men who underwent transrectal ultrasonography at our hospital during routine health examinations were
included in this study. Those who had undergone a prior biopsy or surgery for prostate disease, were suspected of having urinary
tract infection, or were taking BPH/LUTS or metabolic syndrome medications were excluded. BPH/LUTS was deﬁned as an
International Prostate Symptom Score (IPSS) of ≥8 and a prostate volume (PV) of ≥30cm3.
The subjects had a mean age of 54.1 years, PV of 29.2cm3, prostate-speciﬁc antigen (PSA) level of 1.20ng/mL, and IPSS of 9.2.
The annual PV growth rate was 0.48cm3/year. Age, body mass index (BMI), PSA, basal metabolic rate, apolipoprotein A-1, fasting
blood glucose, high-density lipoprotein (HDL) cholesterol levels were signiﬁcant predictive factors for PV. Age, PSA, apolipoprotein B,
fasting blood glucose, cholesterol, HDL, and low-density lipoprotein (LDL) levels were predictors of BPH/LUTS at the initial health
examination. A decreased fat mass and LDL level were a signiﬁcant risk factor for the development of BPH/LUTS within 5 years in
men without a BPH/LUTS diagnosis at the initial examination.
Metabolic syndrome-related variables were strongly associated with BPH/LUTS and by decreasing fat mass and LDL levels,
development of BPH/LUTS could be prevented within 5 years in healthy Korean men.
Abbreviations: BMI = body mass index, BPH = benign prostatic hyperplasia, CI = conﬁdence interval, HDL = high-density
lipoprotein, IPSS= international prostate symptom score, LDL= low-density lipoprotein, LUTS= lower urinary tract symptoms, OR=
odds ratio, PNI = prognostic nutritional index, PSA = prostate-speciﬁc antigen, PV = prostate volume, TRUS = transrectal
ultrasonography.
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11. Introduction
Benign prostatic hyperplasia (BPH) occurs in aging men,
characterized by the proliferation of smoothmuscle and epithelial
cells within the prostatic transition zone.[1] The enlarged gland
contributes to several lower urinary tract symptoms (LUTS),
including nocturia, incomplete voiding, urgency, and hesitancy.
The natural history of BPH and the risk factors for LUTS
progression have been evaluated in community-based studies,[2,3]
and with data from the placebo arms of several clinical trials.[4,5]
However, most of these studies have been conducted in
Caucasian men.[6,7] Although several studies have reported a
relationship between prostate volume (PV) and prostate-speciﬁc
antigen (PSA) level in men with BPH/LUTS in Asia,[8,9] there are
no studies that investigated the risk factors for BPH/LUTS in
Asian men.
Previous studies have reported several risk factors for the
development and progression of BPH/LUTS, and interestingly,
other than PV and PSA level, metabolic syndromes were found
out to be important determinants in both the development and
progression of LUTS.[10–12] Therefore, by maintaining healthy
lifestyle, including stop smoking and alcohol consumption, and
increase in exercise which leads to normalization of blood
glucose, cholesterol levels, etc, which eventually would decrease
in metabolic syndromes, could alleviate voiding symptoms. Thus,
Park et al. Medicine (2019) 98:42 Medicinein this study, we aimed to evaluate whether the risk factors for
metabolic syndromes, including lifestyle variables, are related to
the predictors of BPH/LUTS at initial diagnosis and for the
development of BPH/LUTS within a 5-year follow-up in a large-
scale health program.2. Materials and methods
2.1. Study population and data collection
This is the retrospective study approved by the institutional
review board (3–2016–0233). Among individuals who presented
at our hospital for routine health examinations between April
2006 and May 2016, healthy men who underwent at least one
transrectal ultrasonography (TRUS) examination were enrolled.
Data on characteristics of the 4880 subjects, including age at the
health examination, body mass index (BMI), medical history,
previous diagnosis of cancer, surgical history, medication types,
smoking status, alcohol drinking status, exercise status, PV, PSA
level, International Prostate Symptom Score (IPSS), and blood
and urine laboratory results, were collected.
Men who had undergone a prior biopsy or surgical treatment
for prostate disease, those who were suspected of having urinary
tract infection on the basis of a urine test revealing >10 white
blood cells/mL, those with metabolic syndrome, and those who
were taking treatment for BPH or metabolic syndrome were
excluded from the analysis. After applying the exclusion criteria,
a total of 4880 men were included for analysis.2.2. Assessments of clinical variables
BMI was calculated as the weight in kilograms divided by the
height in meters squared. The serum PSA level was assayed using
a chemiluminescencemethod and commercially available kits. PV
was calculated by substituting the formula for an ellipsoid, i.e.,
p=6 height lengthwidth, with the height, length, andwidth
of the prostate measured by TRUS. For 1459 men who
underwent two or more serial TRUS examinations, the annual
PV growth rate was calculated as the PV at the latest TRUSminus
the PV at the ﬁrst TRUS, divided by the time elapsed in years
between the two measurements.2.3. Nutrition status evaluation
To evaluate the effect of nutrition status, the prognostic
nutritional index (PNI) was assessed. The PNI values were
calculated using data from blood and urine laboratory results. On
the basis of a previous study, the PNI was calculated as 10 Table 1
Baseline characteristics of the study group.
Total Age 40–49 years Age 5
No. of subjects 4880 1753 (35.9) 19
Age (years) 54.1±8.6 45.6±2.8 54
BMI (kg/m2) 24.4±2.8 24.6±2.9 24
PSA level (ng/mL) 1.20±1.47 0.99±1.19 1.
PV (cm3) 29.2±14.3 26.2±6.9 28
Total IPSS 9.2±6.6 9.3±6.7 9
PV growth rate (cm3/year) 0.48±3.28 0.45±4.16 0.
Data are presented as n (%) or as mean± standard deviation.
BMI=body mass index, IPSS= International Prostate Symptom Score, PSA=prostate-speciﬁc antigen,
2serum albumin (g/dL) + 0.005  total lymphocyte count (per
mm3).[13] A PNI value of at least 50 was deﬁned as normal,
whereas <50 was considered mild malnutrition, <45 was
considered moderate-to-severe malnutrition, and <40 was
considered serious malnutrition.[14] In this study, clinically
signiﬁcant malnutrition was deﬁned as a PNI cut-off value
of <50.2.4. Statistical analysis
BPH/LUTS was deﬁned as an IPSS of ≥8 points concomitant with
a PV of ≥30cm3. The patients were categorized according to the
level of smoking (non-smoker/ex-smoker vs current smoker),
alcohol consumption (non-drinker/intermittent drinker vs cur-
rent drinker), and exercise (non-exerciser/intermittent exerciser
vs current exerciser). Pearson’s chi-square test was used to
compare the distributions of categorical baseline clinical
characteristics. For continuous variables, means and standard
deviations were compared with Student’s t-test. Additionally,
simple and multiple logistic regression analyses with forward
stepwise procedures were used. Statistical analyses were
performed with the SPSS 23.0 (Chicago, IL, USA). All tests
were two sided, and signiﬁcance was set at P < .05.3. Results
3.1. Demographic characteristics
The baseline characteristics of the subjects are shown in Table 1.
A total of 4880 subjects were available at baseline, with a mean
age, PV, and PSA levels were 54.1 ± 8.6 years, 29.2±14.3cm3,
and 1.20±1.47ng/mL, respectively. The mean IPSS was 9.2±
6.6. The PSA level and PV signiﬁcantly increased with age,
however, there was no signiﬁcant association between total IPSS
and age. The mean annual PV growth rate was 0.48cm3/year.
The annual PV growth rate increased with increasing age,
especially from age >70 years.3.2. Predictors of BPH/LUTS at the initial health
examination
Among 4880 subjects, men with BPH/LUTS (n=3529, 72.3%)
were signiﬁcantly older than men without BPH/LUTS (n=1351,
27.7%) (P< .001) at the initial health examination (Table 2). The
PSA levels, PV, total IPSS, and quality of life score were
signiﬁcantly higher in those with BPH/LUTS. For metabolic
factors, basal metabolic rate, apolipoprotein B, cholesterol, high-
density lipoprotein (HDL), and low-density lipoprotein (LDL)0–59 years Age 60–69 years Age > 70 years P-Value
92 (40.8) 883 (18.1) 252 (5.2)
.5±2.8 64.2±2.8 74.2±3.8 <.001
.5±2.7 24.1±2.7 23.6±2.9 <.001
13±1.17 1.56±2.05 2.02±2.31 <.001
.8±8.1 33.9±27.6 36.6±17.3 <.001
.2±6.6 8.8±6.5 9.2±7.0 .468
47±2.47 0.46±2.62 0.67±4.52 .324
PV=prostate volume, TV= transitional zone volume.
Table 2
Characteristics of subjects stratiﬁed into groups with and without BPH/LUTS at the initial health examination.
Total BPH/LUTS (+) BPH/LUTS () P-Value
No. of subjects 4880 3529 (72.3) 1351 (27.7)
Age (years) 54.0±8.6 54.7±8.6 52.6±8.2 <.001
BMI (kg/m2) 24.4±2.8 24.4±2.7 24.4±2.8 .622
PSA level (ng/mL) 1.20±1.47 1.29±1.58 1.11±0.97 <.001
PV (cm3) 29.2±14.3 31.5±16.2 23.5±4.2 <.001
Total IPSS 9.2±6.6 11.4±6.3 3.3±2.5 <.001
Quality of life 2.6±1.4 2.8±1.2 1.8±1.3 <.001
Basal metabolic rate (kcal/day) 1311.7±139.9 1308.5±139.6 1319.8±140.3 .023
Fat mass (kg) 16.6±4.8 16.6±4.7 16.5±5.0 .449
Apolipoprotein A-1 (mg/dL) 140.9±22.8 140.4±22.1 142.5±24.3 .124
Apolipoprotein B (mg/dL) 100.9±24.8 99.4±24.4 104.5±25.3 <.001
Fasting blood glucose (mg/dL) 103.3±23.4 102.9±22.3 104.5±26.1 .304
Triglyceride (mg/dL) 142.0±91.8 140.5±89.3 145.6±97.5 .076
Cholesterol (mg/dL) 195.9±36.0 194.9±35.9 198.3±36.2 .003
HDL (mg/dL) 48.0±11.1 47.6±10.8 48.9±11.9 .006
LDL (mg/dL) 125.5±33.2 124.1±32.8 129.1±33.9 <.001
PNI 47.1±2.7 47.0±2.7 47.2±2.7 .018
PNI <50 3811 (78.1) 2769 (78.5) 1042 (77.1) .028
Smoking (current) 1574 (32.3) 1140 (32.3) 434 (32.1) .024
Alcohol (current) 2557 (52.4) 1783 (50.5) 774 (57.3) .062
Exercise (current) 455 (9.3) 229 (6.5) 226 (16.7) .173
Data are presented as n (%) or as mean± standard deviation.
BMI=body mass index, BPH=benign prostatic hyperplasia, HDL=high-density lipoprotein cholesterol, IPSS= International Prostate Symptom Score, LDL= low-density lipoprotein cholesterol, LUTS= lower
urinary tract symptoms, PNI=prognostic nutritional index, SA=prostate-speciﬁc antigen, PV=prostate volume.
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of patients with PNI <50 (considered malnutrition status) was
higher among men with BPH/LUTS than among those without
BPH/LUTS. Among lifestyle variables, only smoking status were
signiﬁcantly associated between those with and without BPH/
LUTS.
In the multivariate logistic regression analysis of BPH/LUTS
diagnosis at the initial health examination, age (odds ratio
[OR]=1.04, 95% conﬁdence interval [CI] 1.023–1.053; P
< .001), PSA (OR=1.26, 95% CI 1.083–1.461; P= .003),
apolipoprotein B (OR=0.98, 95% CI 0.972–0.995; P= .006),Table 3
Results of univariate and multivariate logistic regression analyses fo
Univariate analysis
Odds ratio (95% CI)
Age 1.03 (1.022–1.038)
BMI 1.01 (0.952–1.029)
PSA level 1.42 (1.301–1.554)
Basal metabolic rate 5.47 (0.999–1.000)
Fat mass 1.00 (0.989–1.016)
Apolipoprotein A-1 1.00 (0.991–1.000)
Apolipoprotein B 0.99 (0.988–0.996)
Fasting blood glucose 1.00 (0.995–1.000)
Triglyceride (mg/dL) 1.00 (0.999–1.000)
Cholesterol 1.00 (0.996–0.999)
HDL 0.99 (0.984–0.995)
LDL 1.00 (0.994–0.997)
PNI 0.98 (0.952–0.999)
Smoking (current) 0.83 (0.707–0.975)
Alcohol (current) 0.94 (0.696–1.009)
Exercise (current) 1.31 (0.888–1.933)
Data are presented as mean± standard deviation. Only variables found to be signiﬁcant in the univaria
BMI=body mass index, BPH=benign prostatic hyperplasia, CI=conﬁdence interval, IPSS= Internationa
PSA=prostate-speciﬁc antigen, PV=prostate volume.
3fasting blood glucose (OR=0.99, 95% CI 0.988–0.998;
P= .005), cholesterol (OR=1.04, 95% CI 1.025–1.046; P
< .001), HDL (OR=0.96, 95% CI 0.946–0.973; P< .001),
and LDL (OR=0.97, 95% CI 0.962–0.978; P< .001) were
identiﬁed as signiﬁcant variables (Table 3).3.3. Predictors of the development of BPH/LUTS within a
5-year follow-up of men without BPH/LUTS at baseline
Among men without a BPH/LUTS diagnosis at the initial
examination, 262 (33.8%) were diagnosed as having BPH/LUTSr predictors of BPH/LUTS at the initial health examination.
Multivariate analysis
P-Value Odds ratio (95% CI) P-Value
<.001 1.04 (1.023–1.053) <.001
.656
<.001 1.26 (1.083–1.461) .003
<.001 1.00 (1.000–1.002) .118
.751
.075
<.001 0.98 (0.972–0.995) .006
.042 0.99 (0.988–0.998) .005
.069
.004 1.04 (1.025–1.046) <.001
<.001 0.96 (0.946–0.973) <.001
<.001 0.97 (0.962–0.978) <.001
.039 1.01 (0.969–1.062) .544
.024 0.85 (0.652–1.097) .206
.063
.173
te analysis were included in the multivariate analysis.
l Prostate Symptom Score, LUTS= lower urinary tract symptoms, PNI=prognostic nutritional index,
Table 4
Results of univariate and multivariate logistic regression analyses for predictors of the development of BPH/LUTS during a 5-year follow-
up of men without BPH/LUTS at baseline.
Univariate analysis Multivariate analysis
Odds ratio (95% CI) P-Value Odds ratio (95% CI) P-Value
Age 1.01 (0.996–1.032) .134
BMI 0.95 (0.900–1.000) .050
PSA level 1.02 (0.905–1.156) .714
Basal metabolic rate 0.84 (0.999–1.001) .800
Fat mass 0.97 (0.940–0.998) .038 0.93 (0.879–0.984) .012
Apolipoprotein A-1 1.01 (0.997–1.017) .185
Apolipoprotein B 0.99 (0.975–0.996) .009 1.00 (0.971–1.020) .710
Fasting blood glucose 1.00 (0.989–1.002) .182
Triglyceride (mg/dL) 1.00 (0.999–1.000) .078
Cholesterol 1.00 (0.991–0.999) .017 1.03 (1.009–1.041) .002
HDL 1.00 (0.986–1.013) .918
LDL 0.99 (0.989–0.999) .010 0.97 (0.950–0.983) <.001
PNI 0.97 (0.917–1.021) .230
Smoking (current) 0.96 (0.658–1.407) .841
Alcohol (current) 1.64 (1.004–2.671) .048 1.14 (0.582–2.222) .707
Exercise (current) 1.93 (0.802–4.633) .143
Data are presented as mean± standard deviation. Only variables found to be signiﬁcant in the univariate analysis were included in the multivariate analysis.
BMI=body mass index, BPH=benign prostatic hyperplasia, CI= conﬁdence interval, IPSS= International Prostate Symptom Score, LUTS= lower urinary tract symptoms, PNI=prognostic nutritional index,
PSA=prostate-speciﬁc antigen, PV=prostate volume.
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follow-up period had a signiﬁcantly lower fat mass, apolipopro-
tein B, cholesterol, LDL, and higher alcohol drinking status at the
initial examination.
In the multivariate analysis, fat mass (OR=0.93, 95% CI
0.879–0.984; P= .012), cholesterol (OR=1.03, 95% CI 1.009–
1.041; P= .002), and LDL (OR=1.14, 95% CI 0.950–0.983;
P< .001) were signiﬁcant risk factors for the development of
BPH/LUTS within 5 years (Table 4).4. Discussion
In this study, we investigated the risk factors for BPH/LUTS of
4880 healthy men without prostate cancer, urinary tract
infection, BPH/LUTS medication, or metabolic syndrome at
baseline. The various variables including metabolic syndrome
components, such as apolipoprotein B, fasting blood glucose,
cholesterol, HDL, and LDL levels, were signiﬁcantly associated
with BPH/LUTS at initial diagnosis. Among the metabolic
syndrome variables, decreased fat mass and LDL level were
predictive factors for the development of BPH/LUTS within 5
years in men who did not have these conditions at baseline.
Smoking, alcohol consumption, and exercise were not identiﬁed
as preventive factors for the development of BPH/LUTS.
Several reports have investigated the normal reference ranges
for PV, PSA level, and annual PV change rates in men, using a
nationwide screening population.[15,16] The mean PV in each 10-
year age group was similar to that reported in studies in
Japanese[16] and Korean[9,17] populations, but lower than that in
studies on Caucasians[15] and African Americans.[18] We found
that the serum PSA level in our study population was slightly
higher than that reported in another Korean population.[8] In our
screening population, the estimated annual PV growth rate was
0.48cm3/year, which was similar to the rates reported in previous
community-based studies (0.3–0.6cm3/year).[3,15,17]
Previous studies reported that age, BMI, PSA level, and the
presence of metabolic syndrome were signiﬁcant factors4associated with PV.[17,19,20] In a small case-control study,
HDL level was shown to be negatively associated with prostate
enlargement.[21] In a meta-regression analysis, the major
metabolic syndrome-related determinant of BPH was HDL
level.[22] After evaluating the parameters associated with PV,
including those suggested in previous studies, we found that age,
BMI, PSA, basal metabolic rate, apolipoprotein A-1, fasting
blood glucose, and HDL were statistically signiﬁcant factors
associated with PV. Similar to previous study, HDL level was
negatively associated with PV. In particular, apolipoprotein A-1,
as the major protein in HDL which plays an important role
during the process of reverse cholesterol transport,[23] was found
to be positively associated with PV with signiﬁcance.
In contrast to the ﬁndings of association of several metabolic
syndrome-related factors with PV, different metabolic syndrome-
related factors were found out to be associated with BPH/LUTS.
Among metabolic syndrome-related factors, apolipoprotein B,
fasting blood glucose, cholesterol, HDL, and LDL were
signiﬁcantly associated with BPH/LUTS at initial diagnosis in
multivariate analysis. Basal metabolic rate and apolipoprotein
A-1, which were associated with PV, were not found to be
associated with BPH/LUTS, however, apolipoprotein B, choles-
terol, and LDL were found out to be associated with BPH/LUTS.
Notably, apolipoprotein B is known to regulate metabolic
syndrome. Apolipoprotein B is a high molecular weight protein
that is strongly correlated with the values of total cholesterol and
HDL.[24] High apolipoprotein B levels predict atherogenic
alterations, based on the known association between apolipo-
protein B level and cardio-cerebrovascular complications.
Moreover, evidence has shown signiﬁcant associations between
apolipoprotein B level and chronic degenerative complica-
tions.[25,26] Therefore, it is presumed that apolipoprotein B level
may be associated with vascular disease of the organ involved in
urination and voiding.
Pan et al reported that weight; levels of fasting blood glucose,
HDL, total cholesterol, and total glycerides; BMI; systolic and
diastolic blood pressure; residual urine volume; total PV; and
Park et al. Medicine (2019) 98:42 www.md-journal.comannual PV growth rate were signiﬁcantly different between men
with moderate LUTS and those with severe LUTS.[27] The results
of our analysis of subjects stratiﬁed into groups with and without
BPH/LUTS at the initial health examination were similar to the
ﬁndings of this previous report (Table 2). Notably, current
smoking was signiﬁcantly associated with a lower risk of BPH/
LUTS diagnosis at the initial health examination. However,
smoking had no effect on decreasing the risk of BPH/LUTS
development. Although smoking is a known risk factor of several
disorders, the relationship between smoking and BPH/LUTS
remains controversial. Nicotine in cigarettes has been shown to
lead to increased dihydrotestosterone level in the prostate and
increased sympathetic nervous system activity, contributing
greatly to BPH and LUTS.[28,29] However, Platz et al concluded
that smoking decreases prostate enlargement to a degree, and
even argued for a protective effect of smoking against prostate
enlargement.[30] In this way, smoking increases the bladder
activity through the sympathetic nervous system and may
potentially aggravate overactive bladder symptoms. It was
presumed that the autonomic muscle relaxation was caused by
nicotine, with the ﬁrst sphincter being autonomic. Therefore,
further studies are needed to investigate the effect of smoking on
BPH/LUTS.
In this study, exercise was not found to be signiﬁcantly
associated with BPH/LUTS. However, there is a growing body of
evidence supporting a protective role for exercise in reducing the
risk of developing BPH/LUTS.[31] Several hypotheses have been
proposed, and favorable changes in hormonal milieu (androgen
levels, insulin, and metabolic syndrome) could be associated.
Other hypotheses include decreased resting sympathetic tone in
the prostate and reduction in prostatic inﬂammation by
decreasing oxidative damage.[31] However, for any of these,
causal relationships have not been established. Moreover, most
studies have described an inverse relationship between exercise
and BPH/LUTS, although some have not clearly demonstrated a
positive role for exercise on BPH/LUTS and have provided
conﬂicting results. We think that this may be due to differences in
deﬁning exercise and BPH/LUTS and that the age of starting
exercise may warrant consideration.[31]
Published reports about predictors of BPH/LUTS development
are scarce. Dahle et al suggested that risk factors reﬂecting
metabolic syndrome, such as the waist-to-hip ratio, inﬂuence the
development of BPH/LUTS.[32] Interestingly, the present study
found that a decreased LDL level was a signiﬁcant predictor of
BPH/LUTS development within a 5-year follow-up period in men
without BPH/LUTS. Among the metabolic syndrome compo-
nents, we predicted HDL as a major factor in the development of
BPH/LUTS because increasing HDL showed a negative effect on
both PV and IPSS, which is in agreement with the results of
previous studies.[22] Therefore, maintaining a high HDL level has
been considered a preventive strategy against BPH/LUTS.
However, the predictor of the development of BPH/LUTS was
LDL, not HDL. To interpret these results, we further evaluated
nutrition status; however, we did not identify any obvious
ﬁndings. We assumed that this is because of the intercorrelation
between each metabolic syndrome component, although this
theory requires further validation.
BPH/LUTS is common among older adult men; however, it
may be linked to malignant disease of the prostate. A large recent
population-based European study established a clear association
between LUTS and the subsequent risk of prostate cancer.[33]
A recent study by Cormio et al attempted to identify cheap and5non-invasive clinical parameters with which to accurately predict
prostate cancer risk, since imaging has not signiﬁcantly increased
the accuracies of prostate cancer risk prediction models.[34] We
believe that incorporating BPH/LUTS as a parameter for
predicting prostate cancer would be interesting and might help
increase the accuracy of predicting prostate cancer risk.
Therefore, for future study, we are planning to investigate
associations for newly diagnosed prostate cancer in men with and
without BPH/LUTS.
This study has several limitations. First, the study was
conducted at a single institution and may have been subject to
selection bias. Most of those screened at our hospital are healthy
people who undergo routine health examinations. Moreover, the
data were not derived from a community-based population.
Further large-scale studies in the general population will be
necessary to conﬁrm our results. Second, although the IPSS is a
validated patient-administered questionnaire that is useful to
quantify the severity of LUTS, IPSS should not be used alone. The
quality of life score is more important than IPSS.[35] However,
our criteria of BPH/LUTS, such as the various deﬁnitions of BPH/
LUTS by many international guidelines and local studies, did not
include the quality of life score as a component of the deﬁnition.
This might indicate that that a higher quality of life score has a
preventive effect against the development of BPH/LUTS. Future
studies are needed to validate our ﬁndings.
In conclusion, metabolic syndrome-related variables, including
fat mass, apolipoprotein B, fasting blood glucose, cholesterol,
HDL, and LDL levels, are signiﬁcantly associated with develop-
ment of BPH/LUTS, and increasing fat mass and LDL levels
appear to be important to preventing the development of BPH/
LUTS. Further studies investigating the intercorrelation between
each metabolic syndrome component are warranted to validate
the results of the present study.Acknowledgments
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